Loading...
Market
Will CMG1A46 generate over $500 million in sales within first year?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
GSK financial reports or industry sales data
Story
British GSK Acquires Experimental Lupus Drug from Chimagen Biosciences for Up to $850 Million
Oct 29, 2024, 12:27 PM
British drugmaker GSK has entered into an agreement to acquire CMG1A46, an experimental drug from Chinese biotech firm Chimagen Biosciences, for up to $850 million. This acquisition includes a $300 million upfront payment and aims to expand GSK's pipeline of potential treatments for lupus. The drug, CMG1A46, is a clinical-stage dual CD19 and CD20-targeted T cell-engager, which is expected to enhance GSK's immunology portfolio.
View original story
Similar markets
Yes • 50%
No • 50%
Above $500 million • 50%
Below or equal to $500 million • 50%
Less than 100,000 • 25%
100,000 to 500,000 • 25%
500,000 to 1,000,000 • 25%
More than 1,000,000 • 25%